We applied a biglycan/BGN antibody (see Methods) to stain 70 samples with accessible tumor sections from the current transcriptome analysis cohort (screening set) and 56 samples from an independent molecularly diagnosed ST-EPN ZFTA-RELA cohort applied in previous studies (validation set) [27, 37]. This evidence concerns the gene BGN and neoplasm.